Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Mitoquidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 7/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | PGAM1 | P18669 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mitoquidone SCHEMBL93910 | 0.92 | MAOA (0.43) | MAPTEGFRMAPK1KMT2ALMNA | |
| SCHEMBL10376448 | 0.82 | MAOA (0.50) | MAPTMAPK1KMT2ALMNAMAOA | |
| SCHEMBL10376475 | 0.81 | MAPT (0.45) | MAPTEGFRMAPK1KMT2ALMNA | |
| SCHEMBL10376512 | 0.81 | ALDH1A1 (0.51) | MAPTMAPK1KMT2ALMNAMAOA | |
| SCHEMBL10376125 | 0.79 | MAPT (0.46) | MAPTEGFRMAPK1KMT2ALMNA | |
| SCHEMBL10376490 | 0.76 | ACHE (0.32) | MAOA | |
| SCHEMBL10334167 | 0.75 | MAPT (0.36) | MAPTEGFRMAPK1KMT2ALMNA | |
| SCHEMBL10376478 | 0.69 | MAPT (0.39) | MAPTEGFRMAPK1KMT2ALMNA | |
| SCHEMBL10376481 | 0.68 | ALOX15 (0.48) | MAPTEGFRMAPK1KMT2ALMNA | |
| SCHEMBL10378104 | 0.65 | MAOA (0.38) | MAPTEGFRMAPK1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11167001-B2 | Weight management composition | EXERKINE CORPORATION (CA) | 2021-11-09 | — | — | US | disclosed |
| US-20190350997-A1 | Weight Management Composition | EXERKINE CORPORATIOIN (CA) | 2019-11-21 | — | — | US | disclosed |